Oncternal Therapeutics Valuation
| ONCT Stock | USD 0.71 0.43 37.72% |
Oncternal Therapeutics is undervalued. Oncternal Therapeutics holds a recent Real Value of $1.01 per share. The prevailing price of the company is $0.71. Our model determines the value of Oncternal Therapeutics from analyzing the company fundamentals such as Current Valuation of (12.29 M), return on equity of -1.5, and Shares Owned By Insiders of 9.23 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Oncternal Therapeutics' valuation include:
Price Book 0.2297 | Enterprise Value -12.3 M | Enterprise Value Ebitda 0.1466 | Price Sales 0.9724 | Enterprise Value Revenue 0.8526 |
Undervalued
Today
Please note that Oncternal Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Oncternal Therapeutics is based on 3 months time horizon. Increasing Oncternal Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Oncternal Therapeutics' intrinsic value may or may not be the same as its current market price of 0.71, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.71 | Real 1.01 | Target 1.93 | Hype 0.89 | Naive 1.04 |
The intrinsic value of Oncternal Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Oncternal Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Oncternal Therapeutics helps investors to forecast how Oncternal stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Oncternal Therapeutics more accurately as focusing exclusively on Oncternal Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Oncternal Therapeutics' intrinsic value based on its ongoing forecasts of Oncternal Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Oncternal Therapeutics' closest peers.
Oncternal Therapeutics Cash |
|
Oncternal Valuation Trend
Oncternal Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Oncternal Therapeutics' financial worth over time. Using both Oncternal Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Oncternal Therapeutics Total Value Analysis
Oncternal Therapeutics is now forecasted to have valuation of (12.29 M) with market capitalization of 2.1 M, debt of 318 K, and cash on hands of 78.9 M. The negative valuation of Oncternal Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Oncternal Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(12.29 M) | 2.1 M | 318 K | 78.9 M |
Oncternal Therapeutics Investor Information
The company has price-to-book ratio of 0.23. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Oncternal Therapeutics recorded a loss per share of 11.69. The entity last dividend was issued on the 10th of June 2019. The firm had 1:20 split on the 8th of January 2024. Based on the key indicators related to Oncternal Therapeutics' liquidity, profitability, solvency, and operating efficiency, Oncternal Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Oncternal Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Oncternal Therapeutics has an asset utilization ratio of 2.14 percent. This implies that the Company is making $0.0214 for each dollar of assets. An increasing asset utilization means that Oncternal Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Oncternal Therapeutics Ownership Allocation
Oncternal Therapeutics holds 9.23 pct. of its outstanding shares held by insiders and 12.07 pct. owned by third-party entities.Oncternal Therapeutics Profitability Analysis
The company reported the previous year's revenue of 785 K. Net Loss for the year was (39.48 M) with loss before overhead, payroll, taxes, and interest of (31.49 M).About Oncternal Therapeutics Valuation
The stock valuation mechanism determines Oncternal Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Oncternal Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Oncternal Therapeutics. We calculate exposure to Oncternal Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Oncternal Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -29 M | -27.5 M | |
| Pretax Profit Margin | (50.29) | (47.78) | |
| Operating Profit Margin | (53.14) | (50.48) | |
| Net Loss | (50.29) | (47.78) | |
| Gross Profit Margin | (36.90) | (35.06) |
Oncternal Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Oncternal Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 2.9 M |
Oncternal Therapeutics Current Valuation Indicators
Oncternal Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Oncternal Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Oncternal Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Oncternal Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Oncternal Therapeutics' worth.Additional Tools for Oncternal Stock Analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.